Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 244.84 USD 1.81% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Penumbra Inc?
Write Note

Penumbra Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Penumbra Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Penumbra Inc
NYSE:PEN
Non-Reccuring Items
-$110.3m
CAGR 3-Years
-110%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Non-Reccuring Items
-$465m
CAGR 3-Years
-22%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Non-Reccuring Items
-$167m
CAGR 3-Years
34%
CAGR 5-Years
-5%
CAGR 10-Years
13%
Stryker Corp
NYSE:SYK
Non-Reccuring Items
-$466m
CAGR 3-Years
23%
CAGR 5-Years
11%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Non-Reccuring Items
-$252m
CAGR 3-Years
-24%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Non-Reccuring Items
-$4.2m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Penumbra Inc
Glance View

Market Cap
9.4B USD
Industry
Health Care

Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth trajectory in a market with substantial demand. As an investment opportunity, Penumbra Inc. stands out not only for its robust pipeline of innovative technologies but also for its impressive financial performance. The company has demonstrated strong revenue growth driven by increasing market adoption of its products and strategic expansions into new therapeutic areas. With healthcare's ongoing shift toward minimally invasive treatments, Penumbra is ideally positioned to capitalize on this trend, supported by a team of experienced professionals and a culture of innovation. For investors, Penumbra offers a compelling blend of growth prospects and the potential for long-term returns as it continues to redefine standards of care in the medical device industry.

PEN Intrinsic Value
106.95 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Penumbra Inc's Non-Reccuring Items?
Non-Reccuring Items
-110.3m USD

Based on the financial report for Sep 30, 2024, Penumbra Inc's Non-Reccuring Items amounts to -110.3m USD.

What is Penumbra Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-110%

Over the last year, the Non-Reccuring Items growth was -506%. The average annual Non-Reccuring Items growth rates for Penumbra Inc have been -110% over the past three years .

Back to Top